COVID-19 疫苗的免疫原性、疗效和安全性：截至 2021 年 12 月 31 日已发表数据的更新。
Immunogenicity, efficacy and safety of COVID-19 vaccines: an update of data published by 31 December 2021.
机构信息
Research Network of Immunity and Health (RNIH), Beijing Institutes of Life Science, Chinese Academy of Sciences, Beijing 100101, China.
Key Laboratory of Tropical Translational Medicine of Ministry of Education, School of Tropical Medicine and Laboratory Medicine, The First Affiliated Hospital, Hainan Medical University, Hainan 571199, China.
出版信息
Int Immunol. 2022 Dec 31;34(12):595-607. doi: 10.1093/intimm/dxac031.
The unprecedented coronavirus disease 2019 (COVID-19) pandemic has caused a disaster for public health in the last 2 years, without any sign of an ending. Various vaccines were developed rapidly as soon as the outbreak occurred. Clinical trials demonstrated the reactogenicity, immunogenicity and protection efficacy in humans, and some of the vaccines have been approved for clinical use. However, waves of infections such as the recently circulating Omicron variant still occur. Newly emerging variants, especially the variants of concern, and waning humoral responses pose serious challenges to the control of the COVID-19 pandemic. Previously, we summarized the humoral and cellular immunity, safety profiles and protection efficacy of COVID-19 vaccines with clinical data published by 21 May 2021. In this review, we summarize and update the published clinical data of COVID-19 vaccines and candidates up to 31 December 2021.
在过去的 2 年中，史无前例的 2019 年冠状病毒病（COVID-19）大流行给公共卫生造成了灾难，而且没有任何结束的迹象。疫情一爆发，各种疫苗就迅速研发出来。临床试验证明了疫苗在人体中的反应原性、免疫原性和保护效果，其中一些疫苗已获准临床使用。然而，像最近流行的奥密克戎变异株这样的感染浪潮仍在发生。新出现的变异株，特别是令人关注的变异株，以及体液免疫反应的减弱，给 COVID-19 大流行的控制带来了严峻挑战。此前，我们根据截至 2021 年 5 月 21 日发表的临床数据，总结了 COVID-19 疫苗的体液和细胞免疫、安全性概况和保护效果。在这篇综述中，我们总结和更新了截至 2021 年 12 月 31 日发表的 COVID-19 疫苗和候选疫苗的临床数据。
Zotero 插件